Unum Therapeutics Announces Start Of First Phase I Clinical Trial Of Cellular Immunotherapy Targeting CD20+ Chronic Lymphocytic Leukemia And Non-Hodgkin Lymphoma

KUALA LUMPUR, Dec 2 (Bernama) -- Unum Therapeutics, a company developing a universal cellular immunotherapy to treat multiple cancers, announced today that recruitment has begun in the first clinical trial of the ATTCK20 therapy. The Phase I study will examine the feasibility, safety and potential efficacy of infusing the ATTCK20 combination therapy in patients with B-cell malignancies and persistent disease following standard therapy. The clinical program commences shortly after the company's official launch in October 2014.

For the full text, click here.